Abstract
Background:
Regional citrate anticoagulation (RCA) is being used more commonly in children for continuous renal replacement therapy. Few reports describe the application of membrane-based therapeutic plasma exchange (mTPE) with RCA in children with liver failure (LF).
Aims:
To explore the application of RCA-mTPE in children with LF.
Methods:
We retrospectively analyzed data from children with LF who underwent RCA-mTPE in the Children's Hospital of Chongqing Medical University's pediatric intensive care unit. We used the total to ionized calcium ratio (T/iCa) > 2.5 as the diagnostic criteria for citrate accumulation (CA). The patients were divided into two groups according to the occureence of CA at the end of RCA-mTPE (CA group: T/iCa > 2.5; NCA group: T/iCa ≤ 2.5). To evaluate the clinical safety and efficacy of RCA-mTPE, the following data from medical records were assessed and compared between groups: clinical characteristics, reasons for LF, RCA-mTPE parameters and duration, laboratory findings, and complications.
Results:
In total, 92 RCA-mTPE treatments were administered to 21 children with LF over 3.8 ± 0.9 h. The following mean values were determined: blood flow rate (QB) = 2.8 ml/kg/min, 4% sodium citrate dose/blood flow rate ratio (QCi/QB) = 1.1(QCi,ml/kg/h); plasma dose/body weight ratio(QP/BW) = 18.5 (QP, ml/kg/h); 10% calcium gluconate dose/blood flow rate ratio (QCa/QB) = 0.2(QCa, ml/kg/h). The mean concentration of iCa in vitro was 0.38 ± 0.07 mmol/L. Citrate accumulation was recorded after 34 (37%) treatments. Hypocalcemia occurred in 11 (12%) and 7 (7.6%) treatments, during and after mTPE, respectively. Three hypotensive and one convulsive events, related to hypocalcemia, and two clotting events occurred during RCA-mTPE. After RCA-mTPE, the patients' pH, HCO3− and Na+ levels, and T/iCa were significantly increased and the total bilirubin (TB), conjugated bilirubin (DB), prothrombin time (PT), activated partial thromboplastin time (APTT), alanine aminotransferase (ALT), aspartate aminotransferase (AST),and ammonia levels were significantly decreased. The TB, DB, and lactic acid levels, before RCA-mTPE, were significantly higher in the CA group than in the NCA group, but there were no significance between the two groups in QB/BW, QCi/QB, and QP/BW, mTPE duration, and estimated amount of citrate metabolized.
Conclusions:
Children with LF undergoing RCA-mTPE are at risk of hypocalcemia. With proper protocol adjustment, however, RCA-mTPE can be used safely and effectively in these patients.
Introduction
The human liver is a vital organ that performs important functions such as synthesis, metabolism, detoxification, immunity, and secretion. The significant reduction of its functions may manifest with conditions such as abnormal blood coagulation, hypoproteinemia, jaundice, and hyperammonemia. Liver failure (LF) can have severe clinical manifestations and result in death. For those with LF, various supportive therapies, such as therapeutic plasma exchange (TPE), molecular adsorbent recirculation, and single-pass albumin dialysis, have been developed as temporary alternatives or bridging treatments before liver transplantation or self-recovery. TPE is the most commonly used technique for acute LF and has been included in European guidelines (1) as a level I, grade 1 recommendation for the management of this condition. Although the value of TPE for acute LF remains controversial (1–3).
Pediatric acute LF is a rare disease with reported mortality rates of 24%–53% (4, 5). It is diagnosed when a patient who has never had liver disease shows biochemical evidence of hepatic injury and significant coagulopathy and encephalopathy (6). Pediatric acute LF is characterized pathologically by hepatic necrosis, hepatocyte destruction, and bile duct proliferation (7). Children with liver injury typically show coagulation dysfunction because the liver is vital for the synthesis of blood coagulation factors.
TPE has been employed for numerous indications over the past decade, including the management of autoimmune and rheumatological diseases, LF, sepsis, hematological disorders, and renal and neurological diseases, and for drug removal (8). It often necessitates anticoagulation, especially when fresh-frozen plasma (FFP) is used as a therapeutic solution. Since most anticoagulants are metabolized in the liver, patients with LF frequently have coagulation disorders, making this procedure challenging (9).
Systemic heparin administration is the most commonly used method for hemodialysis and membrane therapeutic plasma exchange (mTPE), due to its anticoagulatory effect, rapid onset, and low cost; however, it may increase the risk of bleeding (10). Generally, the initial and maintenance doses of heparin maintain an activated clotting time (ACT) or activated partial thromboplastin time (APTT) 1.5–2 times that of normal (11). As the child's coagulation function improves with continuous FFP infusion, the heparin dose should theoretically be increased to maintain appropriate anticoagulation (11, 12). However, it is extremely difficult to increase the dosage of heparin appropriately, and improper adjustment may increase the risk of bleeding or clotting (13).
Citrate inhibits the coagulation cascade by reducing the concentration of ionized calcium (iCa) in the filter via chelation. The filter removes a portion of the calcium citrate complexes, and the remainder enters the systemic circulation and is metabolized rapidly. A constant citrate concentration can theoretically maintain a constant ionized calcium (iCa) concentration, and the blood does not clot when the concentration of iCa is less than 0.33 mmol/L (14). Because FFP contains a stable citrate concentration, it is not necessary to continuously increase the amount of citrate to maintain an appropriate iCa concentration in vitro; in fact, the amount of citrate must be reduced. Thus, the anticoagulant effect of citrate in TPE may be more stable.
Citrate is used more commonly in centrifugal TPE than in membrane-based TPE (mTPE), due to the less risks of citrate accumulation and hypocalcemia caused by greater citrate removal (80% vs. 20%–30%) (15). mTPE is a common PE method that has the advantages of simple operation, low cost, and high separation capacity. Theoretically, these risks can be reduced by adjustment of the mTPE protocol to maintain the citrate dose within the patient's metabolic capacity. Few reports describe the application of mTPE with regional citrate anticoagulation (RCA-mTPE) in children with LF. The purpose of this study was to assess the efficacy, safety, and benefits of the RCA-mTPE protocol for children with LF, to provide a basis for the clinical selection of more optimal anticoagulation methods for this patient population.
Methods
Study design and patients
We conducted this retrospective study with data from children with LF who underwent RCA-mTPE at the Children's Hospital of Chongqing Medical University, Chongqing, China, between February 2020 and November 2021. The study was approved by the hospital's ethics committee [2022 NLS (Y) no. 146]. Written informed consent was obtained from all children's legal guardians. Pediatric acute LF(PALF) was diagnosed in accordance with the national diagnostic criteria for acute LF in children, including: (a) the absence of pre-existing liver disease, (b) severe LD suddenly occurred within 8 weeks of onset, and (c) uncorrectable coagulopathy (after the administration of vitamin K) with prothrombin time (PT) > 20 s and international normalized ratio (INR) > 2.0 in patients without hepatic encephalopathy, or coagulopathy with PT > 15 s or INR > 1.5 in patients with encephalopathy (9, 16).
Inclusion criteria
Meet all the following contents: (a) PALF diagnosis criteria were met and mTPE treatment was performed; (b) mTPE was anticoagulated with RCA.
Exclusion criteria
Meet any one of the following contents: (a) Despite received mTPE, PALF diagnostic criteria were not met; (b) mTPE was anticoagulated with other anticoagulation methods besides RCA.The patients were divided into two groups according to whether T/iCa > 2,5, which was often being used as a diagnostic criterion for citric acid accumulation(CA) (9), after RCA-mTPE (CA group: T/iCa > 2.5; NCA group: T/iCa ≤ 2.5).
RCA-mTPE
RCA-mTPE was performed using the PlasautoΣ blood perfusion device. An appropriate membrane plasma separator was chosen according to each child's weight. When the extracorporeal circulation volume exceeded 10% of the blood volume or the patient had hypotension, a red blood cell suspension and albumin were used to prefill the extracorporeal circulation. Sodium citrate anticoagulant (136 mmol/L citrate; National Medicine Permit no. H20058913; Sichuan Nightingale Biological, China) was delivered to the arterial blood collection end of the device, and 10% calcium gluconate was delivered to the venous return end. The initial RCA-mTPE protocol is shown in Table 1. When the ratio of total to ionized calcium (T/iCa) exceeded 2.5 before RCA-mTPE, the initial blood flow rate, 4% sodium citrate dose, and plasma dose took the smaller value, while the 10% calcium gluconate dose took the larger value. FFP or normal plasma was anticoagulated using citrate dextrose solution II, resulting in a plasma citrate concentration of about 15 mmol/L.
Table 1
| Parameter | Initial parameters | Final parameters |
|---|---|---|
| QB, ml/kg/min | 2–5 | 2.8 |
| QCi/QB | 0.8–1 | 1.1 |
| QCa/QB | 0.1–0.3 | 0.2 |
| QP/BW | 10–25 | 18.5 |
RCA-mTPE parameter settings.
RCA-mTPE, regional citrate anticoagulation for membrane-based therapeutic plasma exchange.
QB, blood flow rate; QCi, 4% sodium citrate dose; QCa, 10% calcium gluconate dose; QP, plasma dose; BW, body weight.
For example, the initial parameters for a 10-kg child are: QB = 30 mL/min, QCi = 30 ml/h, QCa = 6 ml/h, and QP = 200 ml/h.
First, the sodium citrate dose was adjusted to attain an in-vitro iCa concentration of 0.2–0.4 mmol/L; it was increased above this range and reduced below it. The calcium gluconate dose was then adjusted to attain a target in-vivo iCa concentration of 1.0–1.35 mmol/L; it was reduced above this range and increased below it.
In-vivo and in-vitro blood gas analyses (ABL90 FLEX analyzer) were performed 30 min after the start of RCA-mTPE. Routine blood gas and component analyses were performed and biochemical indicators, electrolytes, and coagulation factors were evaluated after RCA-mTPE.
Data collection and variable definitions
The following information was collected from the patients' medical records: reasons for LF, RCA-mTPE parameters and duration, laboratory findings, citrate accumulation (T/iCa > 2.5), hypocalcemia (iCa concentration < 0.9 mmol/L), hypercalcemia (iCa concentration > 1.35 mmol/L), hyponatremia (sodium ion concentration < 135 mmol/L), hypernatremia (sodium ion concentration > 145 mmol/L), metabolic acidosis (bicarbonate concentration < 22 mmol/L), and metabolic alkalosis (bicarbonate concentration > 27 mmol/L). When the waste liquid flow rate equaled the plasma dose + sodium citrate dose, the filter clearance rate was calculated as:where QP is the plasma dose, QCi is the sodium citrate dose, and QB is the blood flow rate. The amount of citrate metabolized by the body was estimated as:
Statistical analysis
The statistical analyses were performed with IBM SPSS (version 21). The chi-squared test and Fisher's exact test were used to assess differences in qualitative data. Continuous variables consistent with normal distribution were reported as mean ± standard deviation and compared using the t test, and without normal distribution were reported as median (first and third quartile) and compared using the Mann–Whitney U test. P-values <0.05 were considered to reflect significance.
Results
Patient characteristics
The sample comprised data from 21 children with LF who underwent 92 RCA-mTPE treatments with an average duration of 3.8 ± 0.9 h. The patients' clinical characteristics are summarized in Table 2.
Table 2
| Parameter | Value |
|---|---|
| N | 21 |
| Sessions, n | 92 |
| Age, months | 22.00 (8.04, 74.00) |
| Body weight, kg | 11.50 (8.50, 20.00) |
| Male gender, male (n, %) | 12.00 (57.14%) |
| PRISM Ⅲ score | 8.86 ± 4.69 |
| Child-Pugh score | 13.00 (11.00,14.00) |
| In-ICU days, days | 14.02 ± 7.05 |
| In-hospital days, days | 25.27 ± 11.43 |
| In-hospital mortality (n, %) | 3.00 (14.29%) |
| 90-day mortality (n, %) | 10 (47.60%) |
| Causes of ALF (n, %) | |
| Drug | 2 (9.52%) |
| Poisoning | 3 (14.29%) |
| Infection | 3 (14.29%) |
| Immune | 4 (19.05%) |
| Metabolic | 5 (23.81%) |
| Biliary tract diseases | 2 (9.52%) |
| Others | 2 (9.52%) |
Patients’ clinical characteristics.
Effect of RCA-mTPE on the clinical indicators
After RCA-mTPE, the patients' total and conjugated bilirubin levels, APTT, aspartate and alanine aminotransferase levels improved significantly, however, the pH, bicarbonate levels, and T/iCa also increased significantly. The in-vivo iCa concentration decreased significantly in CA group and increased significantly in NCA group (Table 3).
Table 3
| Before PE | After PE | P-value | |
|---|---|---|---|
| TB, μmol/L | 227.90 ± 95.60 | 169.30 ± 83.10 | <0.001 |
| DB, μmol/L | 85.80 ± 59.90 | 48.70 ± 37.70 | <0.001 |
| PT, s | 33.90 ± 16.70 | 20.80 ± 9.00 | <0.001 |
| APTT, s | 50.50 ± 16.80 | 43.10 ± 15.30 | <0.001 |
| AST, u/L | 144.50 (53.25, 447.93) | 72.10 (37.25, 183.50) | <0.001 |
| ALT, u/L | 138.50 (51.00, 343.00) | 80.15 (35.75, 157.55) | <0.001 |
| blood ammonia, mmol/L | 78.90 ± 42.40 | 69.90 ± 33.40 | 0.003 |
| blood lactate, mmol/L | 3.10 ± 2.20 | 2.80 ± 1.40 | 0.242 |
| PH | 7.43 ± 0.07 | 7.47 ± 0.08 | <0.001 |
| HCO3−, mmol/L | 25.50 ± 5.60 | 30.50 ± 5.10 | <0.001 |
| iCa2+, mmol/L | 1.18 ± 0.11 | 1.14 ± 0.17 | 0.465 |
| T/iCa | 2.03 ± 0.27 | 2.48 ± 0.51 | <0.001 |
| Na+, mmol/L | 137.10 ± 4.00 | 139.80 ± 3.60 | <0.001 |
| Effects of citric acid-induced fluid load | |||
| Heart rate | 117.37 ± 20.63 | 116.39 ± 21.79 | 0.639 |
| Mean arterial pressure, mmHg | 72.42 ± 16.00 | 78.10 ± 17.17 | 0.002 |
| Diastolic blood pressure, mmHg | 56.14 ± 12.81 | 60.52 ± 14.89 | 0.002 |
| CA group | |||
| PH | 7.42 ± 0.08 | 7.44 ± 0.06 | 0.122 |
| HCO3−, mmol/L | 26.17 ± 6.04 | 28.72 ± 5.39 | 0.001 |
| iCa2+, mmol/L | 1.18 ± 0.11 | 1.05 ± 0.19 | 0.001 |
| NCA group | |||
| PH | 7.43 ± 0.05 | 7.48 ± 0.08 | <0.001 |
| HCO3−, mmol/L | 25.18 ± 5.30 | 31.50 ± 4.67 | <0.001 |
| iCa2+, mmol/L | 1.18 ± 0.12 | 1.24 ± 0.12 | 0.003 |
Biochemical indicators, electrolytes, and blood gas parameters before and after RCA-mTPE.
TB, total bilirubin; DB, direct (conjugated) bilirubin; PT, prothrombin time; APTT, activated partial thromboplastin time; AST, aspartate aminotransferase; ALT, alanine aminotransferase; T/iCa, total to ionized calcium ratio.
Effects of RCA-mTPE on the fluid load and cardiovascular system
The heart rate, diastolic blood pressure, and mean arterial pressure were used to assess the effect of a citrate-induced increase in the fluid load. RCA-mTPE induced significant increases in patients' diastolic blood pressure and mean arterial pressure, but did not affect the heart rate (Table 3).
General data and complications
CA occured in 8 (38.1%) patients, for a total of 34 (36.9%) RCA-mTPE treatments. Before RCA-mTPE, the TB, DB, and lactate levels were significantly higher in the CA group than in the NCA group. The PRISM III score, Child–Pugh score, prothrombin time (PT), APTT, aspartate and alanine aminotransferase levels, ammonia level, blood flow rate/ and plasma dose/body weight ratios, sodium citrate dose/blood flow rate ratio, PE duration, and estimated amount of citrate metabolized did not differ between the two groups (Table 4).
Table 4
| Parameter | NCA group | CA group | P-value |
|---|---|---|---|
| Sessions, N | 58 | 34 | |
| 90-day mortality (%) | 5/12 (41.67%) | 4/9 (44.44%) | 0.623 |
| Before RCA-MTPE | |||
| PRISM Ⅲ score | 12.90 ± 2.10 | 10.20 ± 2.90 | 0.117 |
| Child-Pugh score | 12.50 ± 2.10 | 11.40 ± 3.60 | 0.430 |
| PT (s) | 35.90 ± 17.40 | 48.40 ± 44.30 | 0.152 |
| APTT, (s) | 46.80 ± 15.10 | 59.50 ± 34.00 | 0.065 |
| TB (μmol/L) | 191.00 ± 79.10 | 256.40 ± 110.90 | 0.011 |
| DB (μmol/L) | 63.00 ± 55.20 | 92.90 ± 65.40 | 0.042 |
| ALT (u/L) | 138.50 (51.00, 310.90) | 122.00 (42.50, 389.00) | 0.952 |
| AST, (u/L) | 103.00 (53.00, 386.73) | 204.50 (54.00, 523.20) | 0.363 |
| Lactic acid (mmol/L) | 2.10 ± 1.00 | 3.70 ± 2.60 | 0.003 |
| Serum ammonia (mmol/L) | 68.00 ± 40.00 | 84.00 ± 40.00 | 0.123 |
| Final parameters | |||
| QB/BW, (ml/min) | 2.94 ± 0.38 | 2.89 ± 0.53 | 0.698 |
| QCi/QB | 1.04 ± 0.17 | 1.07 ± 0.22 | 0.518 |
| QCa/QB | 0.20 ± 0.07 | 0.22 ± 0.10 | 0.366 |
| QP/BW, (ml/h) | 18.07 ± 3.92 | 20.00 ± 7.39 | 0.164 |
| DCi (mmol/kg/h) | 0.64 ± 0.10 | 0.66 ± 0.15 | 0.364 |
| PE duration, (h) | 3.67 ± 0.70 | 3.94 ± 1.11 | 0.237 |
Characteristics according to the occurrence of citrate accumulation after RCA-mTPE.
NCA, no citrate accumulation (T/iCa < 2.5 at the end of RCA-mTPE); CA, citrate accumulation (T/iCa > 2.5 at the end of RCA-mTPE); PT, prothrombin time; APTT, activated partial thromboplastin time; TB, total bilirubin; DB, direct (conjugated) bilirubin; ALT, alanine aminotransferase; AST, aspartate aminotransferase; QB, blood flow rate; BW, body weight; QCi, 4% sodium citrate dose; QCa, 10% calcium gluconate dose; QP, plasma dose; DCi, amount of citrate metabolized by the body.
During and after treatment, there were 11 (12%) and 5 (5.4%) episodes of hypocalcemia occurred, respectively, among which there were three episodes of hypotension and one episode of seizure, related to hypocalcemia, occurred. After RCA-mTPE, the incidence of metabolic alkalosis was significantly increased, that of hyponatremia was significantly decreased, and those of hypercalcemia, hypocalcemia, hypernatremia, and bleeding complications did not differ. Two (2.2%) filter clotting events occurred (Table 5).
Table 5
| Before mTPE | After mTPE | p | |
|---|---|---|---|
| iCa2+ < 0.9 mmol.L−1 (n, %) | 0 (0.00%) | 5 (5.43%) | 0.059 |
| iCa2+ > 1.35 mmol.L−1 (n, %) | 5 (5.43%) | 9 (9.78%) | 0.266 |
| PH < 7.35 (n, %) | 10 (10.87%) | 6 (6.52%) | 0.295 |
| PH > 7.45 (n, %) | 36 (39.13%) | 58 (63.04%) | 0.001 |
| HCO3− > 27 mmol.L−1 (n, %) | 36 (39.13%) | 70 (76.09%) | <0.001 |
| HCO3− < 22 mmol.L−1 (n, %) | 29 (31.52%) | 5 (5.43%) | <0.001 |
| Na+ > 145 mmol.L−1 (n, %) | 6 (6.52%) | 5 (5.43%) | 0.756 |
| Na+ < 135 mmol.L−1 (n, %) | 17 (18.48%) | 6 (6.52%) | 0.014 |
| T/iCa > 2.5 (n, %) | 5 (5.43%) | 33 (35.87%) | <0.001 |
| Bleeding (n, %) | 6 (6.50%) | 5 (5.40%) | 0.756 |
| Clotting (n, %) | 2(2.20%) | ||
Complications occurring before and after RCA-mTPE.
iCa2+, in-vivo ionized calcium level; T/iCa, ratio of total to ionized calcium in vivo.
Discussion
Although RCA-TPE has been in clinical use for more than a decade (17), few reports describe RCA-mTPE (8, 18–22), and even fewer provide specific RCA recommendations for mTPE for children with LF. In this study, we evaluated the clinical application of RCA-mTPE in 21 children with LF; the findings indicate that this treatment is safe and effective for this patient population when performed with strict monitoring and adjustment.
RCA-mTPE may be a credible anticoagulation option for children with LF, many of whom have coagulation disorders. Systemic heparin administration for anticoagulation in these patients results in significant prolongation of the APTT and ACT, increasing the risk of bleeding. The coagulation function of these patients improves gradually as FFP is exchanged, making it more challenging to adjust the heparin dose to maintain the desired integration target. The primary benefit of RCA is its ability to maintain effective anticoagulation in the extracorporeal circulation while having a minimal effect on coagulation in vivo (23). The commonly used RCA target in clinical practice is an in-vitro iCa concentration of 0.2–0.4 mmol/L (24–28). Numerous studies have shown that the maintenance of a constant citric acid concentration enables the maintenance of a relatively stable iCa concentration in vitro. Because normal plasma and FFP have the same citrate concentration (15 mmol/L), the flow rate of 4% sodium citrate does not need to be adjusted to maintain the anticoagulation target. As a result, RCA-mTPE may enable the maintenance of a more stable anticoagulant state than does the use of systemic heparin anticoagulation in children with LF. The risk of bleeding during TPE with citrate is significantly lower than that during TPE with heparin (0% vs. 11.8%) (8, 29). In our sample, the incidence of bleeding did not increase after RCA-mTPE and only two episodes (2.2%) of filter clotting, fewer than in other studies with RCA (3.0%–7.3%) (18, 19, 22) and SHA (4.1%) occurred (30).
RCA-mTPE may be feasibly performed in children with LF despite their reduced citrate metabolism. As citrate is metabolized predominantly in the liver, kidneys, and skeletal muscle, LF was historically regarded as a contraindication for this RCA. An increasing number of reports describes the use of RCA with continuous renal replacement therapy (CRRT) in patients with LF, including children (24, 31, 32). These studies have demonstrated that these patients have a diminished ability, rather than complete inability, to metabolize citrate. Thus, we argue RCA-mTPE can be used effectively and safely for children with LF with control of the citric acid dose within the range of the liver's metabolization ability.
Citrate accumulation is the most concerning complication for children with LF undergoing RCA-mTPE, as RCA, LF, and PE all contribute to its risk. T/iCa > 2.5 is used commonly as the diagnostic criterion for citrate accumulation. In this study, the rate of citrate accumulation and T/iCa values increased after RCA-mTPE (37.0% vs. 4.3% and 2.48 ± 0.51 vs. 2.03 ± 0.27, respectively). The percentage of children with at least one episode of citrate accumulation (38.1%) was significantly lower than those reported by Ma et al. (20) for adults who had undergone RCA-mTPE (67%) and by Keila et al. (33) (70%) for children with LF who had undergone RCA-CRRT. Citric acid is a non-toxic physiological organic acid associated with the primary risks of hypocalcemia and moderate metabolic acidosis (34). Thus, the evaluation of the safety of RCA based on the presence of these conditions may be more reasonable.
In theory, the occurrence of citrate accumulation in children with LF who have undergone RCA-mTPE is related primarily to the amount of citric acid that must be metabolized by the body and the individual's ability to metabolize citrate. In this study, the PRISM III score, Child–Pugh score, PT, APTT, ammonia level, blood flow rate/ and plasma dose/body weight ratios, sodium citrate dose/blood flow rate ratio, PE duration, and estimated amount of citrate metabolized did not differ between the CA and NCA group. However, the total and coagulated bilirubin and lactate concentrations were significantly higher in the CA group than in the NCA group. These findings demonstrate that the incidence of citrate accumulation may be related more closely to individuals' ability to metabolize citrate, when RCA-mTPE parameters are not significantly different. They suggest that children with elevated total and coagulated bilirubin and lactate levels who undergo RCA-mTPE are at increased risk of citrate accumulation.
Hypocalcemia is the most severe complication of RCA; in patients undergoing RCA-mTPE, it may be caused by citrate accumulation and insufficient calcium supplementation. When citrate accumulation occurs, reduced breakdown of calcium citrate can result in the reduction of iCa release. Furthermore, waste plasma contains iCa and calcium citrate, which cause more calcium to be lost than is provided by the replenished plasma, necessitating supplementation. Eleven (12.0%) and five (5.4%) hypocalcemia events occurred during and after treatment, respectively, in this study, fewer than reported in adults undergoing RCA-mTPE (16.6%–19.4%) (18, 22) and comparable to the 7% reported by Keila et al. (33) in children with LF undergoing RCA-CRRT. Three (3.2%) episodes of hypocalcemia-related hypotension, one (1.0%) episode of hypocalcemia-related seizure, and no arrhythmia occurred. These complications were relieved by single calcium supplements (10% calcium gluconate, 1 ml/kg). The incidence of hypocalcemia with related symptoms or signs was lower than that reported by Kissling et al. (35) (8.5%) in adult patients and comparable to that reported by Cortina et al. (36) (0.8%) in children undergoing RCA-mTPE.
In addition to citrate accumulation and hypocalcemia, RCA can cause other metabolic complications, such as acid–base and salt imbalances. Relative to that before treatment, the incidence of metabolic alkalosis was significantly higher (pH > 7.45, 63.0% vs. 39.1%, p = 0.001; bicarbonate concentration > 27 mmol/L, 76.1% vs. 39.1%, p < 0.001) and that of hyponatremia was significantly lower (18.5% vs. 6.5%, p = 0.01) after RCA-mTPE. These results reflect increases in the bicarbonate and sodium concentrations due to sodium citrate metabolism. However, RCA-mTPE did not alter the incidences of hypercalcemia, hypocalcemia, or hypernatremia.
Additionally, RCA-mTPE can cause fluid overload. On average, about 9 ml/kg sodium citrate (3 ml/kg/h for 3 h) was used throughout the RCA-mTPE period. The increase in fluid overload resulted in significant increases in the diastolic blood pressure and mean arterial pressure, but did not affect the heart rate. We eliminated the excess fluid with diuresis or subsequent CRRT.
RCA is an effective PE modality for children with LF. The average in-vitro iCa concentration was 0.38 ± 0.07 mmol/L and the average duration of RCA-mTPE was 3.8 ± 0.9 h, with clotting occurring in two (2.1%) sessions. The total and coagulated bilirubin levels, alanine and aspartate aminotransferase levels, PT, and APTT were significantly lower after than before treatment, indicating that the treatment was effective.
The use of different RCA-mTPE parameter settings can result in a variety of complications. The blood flow rate, sodium citrate dose, and plasma dose collectively determine the amount of citrate that enters and needs to be metabolized in the patient's body. In this study, the T/iCa value was significantly higher after than before treatment (2.48 ± 0.51 vs. 2.03 ± 0.27, p < 0.001). Parameters such as the blood flow rate, sodium citrate dose/blood flow rate ratio, and plasma dose/body weight ratio can be reduced to reduce the risk of citrate accumulation.
Limitations
This study is limited by its retrospective nature, which prevented us from establishing causal relationships; we could only examine associations. Furthermore, as individual patients could have received RCA-mTPE, RCA-CRRT, and/or FFP infusions, the pretreatment laboratory indicators may not accurately reflect the patients' liver function or citrate metabolism capacity, thereby influencing the analysis of citrate accumulation.
Conclusions
This study demonstrated that RCA-mTPE is a safe and effective treatment for LF in children. In children undergoing RCA-mTPE, the risk of citrate accumulation is related most to the liver's capacity for citrate metabolism, which decreases more with increasing total and coagulated bilirubin and lactate levels, than with increasing aspartate and alanine aminotransferase and ammonia levels. The risk of citrate accumulation can be reduced by reducing parameters such as the blood flow rate, sodium citrate dose/blood flow rate ratio, and plasma dose/body weight ratio, which makes RCA-mTPE safer for children with LF.
Statements
Data availability statement
The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding author.
Ethics statement
The study was approved by the hospital's Ethics Committee [2022 NLS (Y) no. 146], Children's Hospital of Chongqing Medical University. The studies were conducted in accordance with the local legislation and institutional requirements. Written informed consent for participation was not required from the participants or the participants’ legal guardians/next of kin in accordance with the national legislation and institutional requirements.
Author contributions
JH: conceptualization; data curation; investigation; methodology; validation; draft; software. CW: data curation; investigation. KB: editing; formal analysis; draft; methodology; conceptualization; supervision; validation; project administration. CL: conceptualization; resources; supervision; validation. All authors contributed to the article and approved the submitted version.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
1.
WendonJCordobaJDhawanALarsenFSMannsMNevensFet alEASL clinical practical guidelines on the management of acute (fulminant) liver failure. J Hepatol. (2017) 66:1047–81. 10.1016/j.jhep.2016.12.003
2.
TanEX-XWangM-XPangJLeeG-H. Plasma exchange in patients with acute and acute-on-chronic liver failure: a systematic review. WJG. (2020) 26:219–45. 10.3748/wjg.v26.i2.219
3.
PadmanabhanAConnelly-SmithLAquiNBalogunRAKlingelRMeyerEet alGuidelines on the use of therapeutic apheresis in clinical practice—evidence-based approach from the writing committee of the American society for apheresis: the eighth special issue. J Clin Apher. (2019) 34:171–354. 10.1002/jca.21705
4.
RajanayagamJComanDCartwrightDLewindonPJ. Pediatric acute liver failure: etiology, outcomes, and the role of serial pediatric end-stage liver disease scores. Pediatr Transplant. (2013) 17:362–8. 10.1111/petr.12083
5.
KathemannSBechmannLPSowaJ-PMankaPDechêneAGernerPet alEtiology, outcome and prognostic factors of childhood acute liver failure in a German single center. Ann Hepatol. (2015) 14:722–8. 10.1016/S1665-2681(19)30767-7
6.
BhattHRaoGS. Management of acute liver failure: a pediatric perspective. Curr Pediatr Rep. (2018) 6:246–57. 10.1007/s40124-018-0174-7
7.
LefkowitchJH. The pathology of acute liver failure. Adv Anat Pathol. (2016) 23:144–58. 10.1097/PAP.0000000000000112
8.
YuanFLiZLiXLiuH. Application of regional citrate anticoagulation in membrane therapeutic plasma exchange. Int Urol Nephrol. (2020) 52:2379–84. 10.1007/s11255-020-02581-0
9.
HuFSunYBaiKLiuC. Clinical application of regional citrate anticoagulation for continuous renal replacement therapy in children with liver injury. Front Pediatr. (2022) 10:847443. 10.3389/fped.2022.847443
10.
Kindgen-MillesDBrandenburgerTDimskiT. Regional citrate anticoagulation for continuous renal replacement therapy. Curr Opin Crit Care. (2018) 24:450–4. 10.1097/MCC.0000000000000547
11.
SmytheMAPriziolaJDobeshPPWirthDCukerAWittkowskyAK. Guidance for the practical management of the heparin anticoagulants in the treatment of venous thromboembolism. J Thromb Thrombolysis. (2016) 41:165–86. 10.1007/s11239-015-1315-2
12.
HirshJAnandSSHalperinJLFusterV. Guide to anticoagulant therapy: Heparin.
13.
KitchenS. Problems in laboratory monitoring of heparin dosage: review. Br J Haematol. (2000) 111:397–406. 10.1111/j.1365-2141.2000.02308.x
14.
JamesMFMRocheAM. Dose-response relationship between plasma ionized calcium concentration and thrombelastography. J Cardiothorac Vasc Anesth. (2004) 18:581–6. 10.1053/j.jvca.2004.07.016
15.
AhmedSKaplanA. Therapeutic plasma exchange using membrane plasma separation. CJASN. (2020) 15:1364–70. 10.2215/CJN.12501019
16.
Di GiorgioAD’AntigaL. Acute liver failure in children: is it time to revise the diagnostic criteria?Liver Transpl. (2020) 26:184–6. 10.1002/lt.25693
17.
AntoničMGubenšekJButurović-PonikvarJPonikvarR. Comparison of citrate anticoagulation during plasma exchange with different replacement solutions. Ther Apher Dial. (2009) 13:322–6. 10.1111/j.1744-9987.2009.00733.x
18.
ChristiadiDMercadoCSingerR. Regional citrate anticoagulation in membrane based plasma exchange: safety, efficacy and effect on calcium balance: citrate anticoagulated plasma exchange. Nephrology. (2018) 23:744–7. 10.1111/nep.13088
19.
BetzCBuettnerSGeigerHJungO. Regional citrate anticoagulation in therapeutic plasma exchange with fresh frozen plasma—a modified protocol. Int J Artif Organs. (2013) 36:803–11. 10.5301/ijao.5000245
20.
MaYChenFXuYWangMZhouTLuJet alSafety and efficacy of regional citrate anticoagulation during plasma adsorption plus plasma exchange therapy for patients with acute-on-chronic liver failure: a pilot study. Blood Purif. (2019) 48:223–32. 10.1159/000500408
21.
SiglerKLeeJSrivathsP. Regional citrate anticoagulation with calcium replacement in pediatric apheresis. J Clin Apher. (2018) 33:274–7. 10.1002/jca.21594
22.
HalpinMRChenBSingerRF. Efficacy, safety, and calcium balance of an accelerated citrate anticoagulated membrane-based plasma exchange algorithm. Blood Purif. (2022) 51:70–4. 10.1159/000515827
23.
ChegondiMVijayakumarNTotapallyBR. Management of anticoagulation during extracorporeal membrane oxygenation in children. Pediatr Rep. (2022) 14:320–32. 10.3390/pediatric14030039
24.
SoltysiakJWarzywodaAKocińskiBOstalska-NowickaDBenedykASilska-DittmarMet alCitrate anticoagulation for continuous renal replacement therapy in small children. Pediatr Nephrol. (2014) 29:469–75. 10.1007/s00467-013-2690-6
25.
CortinaGMcRaeRChilettiRButtW. The effect of patient- and treatment-related factors on circuit lifespan during continuous renal replacement therapy in critically ill children. Pediatr Crit Care Med. (2020) 21:578–85. 10.1097/PCC.0000000000002305
26.
LeviMOpalSM. Coagulation abnormalities in critically ill patients. In: O’DonnellJMNáculFE, editors. Surgical intensive care medicine. Cham: Springer International Publishing (2006). p. 222. 10.1186/cc4975
27.
SıkGDemirbugaAAnnayevACitakA. Regional citrate versus systemic heparin anticoagulation for continuous renal replacement therapy in critically ill children. Int J Artif Organs. (2020) 43:234–41. 10.1177/0391398819893382
28.
Raymakers-JanssenPAMALilienMvan KesselIAVeldhoenESWösten-van AsperenRMvan GestelJPJ. Citrate versus heparin anticoagulation in continuous renal replacement therapy in small children. Pediatr Nephrol. (2017) 32:1971–8. 10.1007/s00467-017-3694-4
29.
Soares Ferreira JúniorAHodulikKBartonKDOnwuemeneOA. Hemostatic effects of therapeutic plasma exchange: a concise review. J of Clinical Apheresis. (2022) 37:292–312. 10.1002/jca.21973
30.
JiaoJYuYWeiSTianXYangXFengSet alHeparin anticoagulation versus regional citrate anticoagulation for membrane therapeutic plasma exchange in patients with increased bleeding risk. Renal Fail. (2023) 45:2210691. 10.1080/0886022X.2023.2210691
31.
BrophyPDSomersMJGBaumMASymonsJMMcAfeeNFortenberryJDet alMulti-centre evaluation of anticoagulation in patients receiving continuous renal replacement therapy (CRRT). Nephrol Dial Transplant. (2005) 20:1416–21. 10.1093/ndt/gfh817
32.
KlingeleMStadlerTFliserDSpeerTGroesdonkHVRaddatzA. Long-term continuous renal replacement therapy and anticoagulation with citrate in critically ill patients with severe liver dysfunction. Crit Care. (2017) 21:294. 10.1186/s13054-017-1870-3
33.
RodriguezKSrivathsPRTalLWatsonMNRileyAAHimesRWet alRegional citrate anticoagulation for continuous renal replacement therapy in pediatric patients with liver failure. PLoS One. (2017) 12:e0182134. 10.1371/journal.pone.0182134
34.
SchneiderAGJournoisDRimmeléT. Complications of regional citrate anticoagulation: accumulation or overload?Crit Care. (2017) 21:281. 10.1186/s13054-017-1880-1
35.
KisslingSLegallaisCPruijmMTetaDVogtBBurnierMet alA new prescription model for regional citrate anticoagulation in therapeutic plasma exchanges. BMC Nephrol. (2017) 18:81. 10.1186/s12882-017-0494-9
36.
CortinaGMcRaeRChilettiRButtW. Therapeutic plasma exchange in critically ill children requiring intensive care. Pediatr Crit Care Med. (2018) 19:e97–e104. 10.1097/PCC.0000000000001400
Summary
Keywords
regional citrate anticoagulation, plasma exchange, liver failure, children, citrate accumulation
Citation
Hu J, Wang C, Bai K and Liu C (2023) Clinical application of regional citrate anticoagulation for membrane-based therapeutic plasma exchange in children with liver failure. Front. Pediatr. 11:1206999. doi: 10.3389/fped.2023.1206999
Received
16 April 2023
Accepted
10 October 2023
Published
19 October 2023
Volume
11 - 2023
Edited by
Niranjan Kissoon, University of British Columbia, Canada
Reviewed by
Yuanji Ma, Sichuan University, China Emanuele Buccione, Azienda USL di Pescara, Italy
Updates
Copyright
© 2023 Hu, Wang, Bai and Liu.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Ke Bai baike0052032@sina.com
†These authors have contributed equally to this work and share first authorship
Abbreviations: APTT, activated partial thromboplastin time; CRRT, continuous renal replacement therapy; FFP, fresh frozen plasma; iCa, ionized calcium; LF, liver failure; mTPE, membrane-based therapeutic plasma exchange; PT, prothrombin time; RCA, regional citrate anticoagulation; T/iCa, total to ionized calcium ratio.
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.